The LRRK2 G2019S pathogenic mutation causes LRRK2-associated Parkinson’s disease (L2PD) with incomplete penetrance. LRRK2 non-manifesting carriers (L2NMC) are at PD high risk but predicting pheno-conversion is challenging given the lack of progression biomarkers. To investigate novel biomarkers for PD premotor stages, we performed a longitudinal microRNA (miRNA) assessment of serum samples from G2019S L2NMC followed-up over 8 years. Our cohort consisted of G2019S L2NMC stratified by dopamine transporter single-photon emission computed tomography (DaT-SPECT) into DaT-negative (n = 20) and DaT-positive L2NMC (n = 20), pheno-converted G2019S L2PD patients (n = 20), idiopathic PD (iPD) (n = 19), and controls (n = 40). We also screened a second cohort of L2PD patients (n = 19) and controls (n = 20) (Total n = 158). Compared to healthy controls, we identified eight deregulated miRNAs in DaT-negative L2NMC, six in DaT-positive L2NMC, and one in L2PD. Between groups, the highest miRNA differences, 24 candidate miRNAs, occurred between DaT-positive L2NMC and L2PD. Longitudinally, we found 11 common miRNAs with sustained variation in DaT-negative and DaT-positive L2NMCs compared to their baselines. Our study identifies novel miRNA alterations in premotor stages of PD co-occurring with progressive DaT-SPECT decline before motor manifestation, whose deregulation seems to attenuate after the diagnosis of L2PD. Moreover, we identified four miRNAs with relatively high discriminative ability (AUC = 0.82) between non-pheno-converted DaT-positive G2019S carriers and pheno-converted L2PD patients (miR-4505, miR-8069, miR-6125, and miR-451a), which hold potential as early progression biomarkers for PD.
Parkinson’s disease (PD) is an age-related neurodegenerative movement disorder1 which is characterized by the loss of dopaminergic neurons (DAn) in the substantia nigra pars compacta and Lewy bodies containing α-synuclein in different brain areas2,3. The clinical diagnosis is based on motor symptoms (bradykinesia, rigidity, and resting tremor). Still, prodromal disease stages may course with non-motor symptoms such as REM sleep behavior disorder (RBD), hyposmia, constipation, or depression4,5. Most PD cases are classified as idiopathic PD (iPD) patients, but 5–10% encompass monogenic forms6. Among these, mutations in the leucine-rich repeat kinase 2 gene (LRRK2) leading to LRRK2-associated PD (L2PD) are the most frequent monogenic cause of PD7,8. However, the penetrance of mutations in LRRK2, e.g., G2019S, is incomplete and varies across populations, suggesting the involvement of additional modulators9,10,11,12,13. Thus, LRRK2 non-manifesting carriers (L2NMC) are at a higher risk of PD, but predicting disease onset is challenging due to the lack of early progression biomarkers.
MicroRNAs (miRNAs) are small non-coding RNAs regulating gene expression by mRNA cleavage and translational repression14. MiRNA alterations have been associated with PD15,16, and some miRNAs have been proposed as non-invasive candidate biomarkers17,18. However, longitudinal studies are needed, especially in PD at-risk subjects. Thus, to explore early progression biomarkers, we profiled serum miRNA expression levels in a cohort of G2019S L2NMC from Spain, which we followed-up over 8 years19,20. Given that dopamine transporter single-photon emission computed tomography (DaT-SPECT) correlates with striatal PD DAn loss21,22 and that L2NMC can show reduced striatal ligand uptake before the onset of the motor symptoms23, we stratified our cohort into DaT-positive and DaT-negative G2019S L2NMC20,24. By genome-wide miRNA discovery (2578 miRNAs) and RT-qPCR validation, we investigated differentially expressed miRNAs (DEmiR) in G2019S L2NMC, L2PD patients, iPD, and healthy controls20. Overall, this study tackles early miRNA deregulation at PD premotor stages and evaluates the potential of miRNAs as candidate progression biomarkers for PD.
Cross-sectional genome-wide miRNA analysis
In our cohort of study (Table 1 and Fig. 1a), by genome-wide discovery analysis and under a p value below 0.05 and a fold-change above |1.5|, we identified 21 candidate miRNAs in DaT-negative L2NMC vs. controls and 10 in DaT-positive L2NMC (Fig. 1b, c). We also found 11 candidate miRNAs in G2019S L2PD and 45 in iPD compared to controls. These findings indicate a more pronounced miRNA deregulation effect in iPD than L2PD (Fig. 1d, e and Supplementary Table 1A). In addition, across all four comparisons, we observed an overlap in two or more groups of only 10 (13%) out of the 76 unique miRNAs, thus illustrating that most of the deregulated miRNAs identified at the genome-wide level were group-specific (Fig. 2a). Moreover, in line with previous findings, in iPD cases we found miR-19b-3p as the top deregulated miRNA by the array25,26. Altogether, these results indicate that microRNA deregulation is more prominent in iPD than in L2PD and that specific miRNA changes occur across the continuum of progression stages in G2019S carriers including DaT-negative and DaT-positive L2NMC.
By RT-qPCR, we assessed the expression levels of ten candidate miRNAs found in the genome-wide analysis across different comparisons (Supplementary Table 2) and two additional candidate miRNA earlier reported in iPD (miR-29c-3p)25,27 or PD prodromal stages (miR-451a)28. Using the same serum samples, we validated 8 DEmiR, which were deregulated in one or more G2019S carrier groups (miR-122-5p, miR-16-5p, miR-185-5p, miR-221-3p, miR-3196, miR-4505, miR-451a, and miR-8069) (Fig. 3 and Table 2). Of these, all eight miRNAs were up-regulated in DaT-negative L2NMC, six in DaT-positive L2NMC (miR-122-5p, miR-16-5p, miR-185-5p, miR-3196, miR-4505 and miR-451a), and only one in L2PD (miR-3196). Thus, miR-3196 was the only DEmiR common for all G2019S carriers (Fig. 2b). Moreover, to confirm findings in L2PD, we tested an independent set of L2PD patients and controls of equal size (Table 1) and, in line with the initial results, we observed few differences between L2PD and controls (miR-122-5p) (Supplementary Table 3). Although miR-122-5p but not miR-3196 was the miRNA detected in the validation set, given our limited size, both miRNAs represent proposed candidates for subsequent studies in larger L2PD cohorts. Altogether, these results support the concept of a progressive decline in the number of miRNAs deregulated across the successive progression stages in G2019S carriers. In addition, in iPD cases, we found 9 of the 12 studied miRNAs deregulated (miR-122-5p, miR-16-5p, miR-185-5p, miR-19b-3p, miR-22-3p, miR-221-3p, miR-29c-3p, miR-451a, and miR-8069), again detecting greater miRNA deregulation in iPD than in L2PD. Lastly, miR-19b-3p and miR-29c-3p, which were earlier reported as DEmiR in iPD and idiopathic RBD25,26,27,29,30, showed significant changes only in iPD but not in L2PD nor L2NMC, thus indicating differential miRNA deregulation between iPD and the continuum of progression stages in G2019S carriers, at least for these two specific miRNAs.
Comparison of progression stages in G2019S carriers
We next inquired about miRNA differences occurring across the continuum of progression stages in G2019S carriers. To this end, using genome-wide miRNA data, we first performed pair-wise comparisons among DaT-negative L2NMC, DaT-positive L2NMC, and L2PD (Fig. 4a–c and Supplementary Table 1B). We found modest miRNA changes between DaT-negative and DaT-positive L2NMC despite their different DaT-SPECT status (miR-7110-5p and miR-4445-3p). However, we observed that most miRNA differences occurred between DaT-positive L2NMC and L2PD patients with overt disease (24 miRNAs), thus suggesting specific miRNA deregulation occurring along with changes in disease status. Moreover, we exploratorily assessed potential miRNA changes related to pheno-conversion by comparing DaT-positive L2NMC non-pheno-converted after 8 years of follow-up (n = 16) vs. all pheno-converted subjects, i.e., L2PD discovery (n = 20) and validation (n = 19) sets, and DaT-positive L2NMC which pheno-converted during the study (n = 4) (total n = 43). We identified four miRNAs significantly associated with pheno-conversion including miR-4505 (adj. p = 0.0006), miR-8069 (adj. p = 0.0035), and miR-6125 (adj. p = 0.0280) and a borderline trend for miR-451a (adj. p = 0.0828) (Supplementary Table 4). Subsequently, when assessing the discriminative capacity of these four miRNAs to identify pheno-conversion, an area under the curve (AUC) of 0.82 (95% CI: 0.71–0.93) was observed to discern pheno-converted from non-pheno-converted G2019S carriers (Fig. 5). These four miRNAs hold potential as candidate pheno-conversion biomarkers and could be prioritized in subsequent studies.
To further assess specific miRNA changes across time before motor manifestation, by RT-qPCR, we assessed the longitudinal expression levels of the same 12 cross-sectional miRNA in L2NMC. To this end, we used the DaT-negative and DaT-positive L2NMC cross-sectional serum samples as the reference (baseline)31, and compared it to their seriated samples after 4 (time point 2) and 8 years (time point 3) of follow-up. Compared to their respective baselines, longitudinal time points 2 and 3 from DaT-negative and DaT-positive L2NMC20 showed significant miRNA variation for 11 of the 12 studied miRNAs (Table 3 and Fig. 6). More specifically, 5 DEmiR showed continued expression variation which was consistent across both follow-up time points in DaT-negative and DaT-positive L2NMC (miR-16-5p, miR-19-5p, miR-22-3p, miR-451a, and miR-6125), indicating longitudinally sustained expression changes for some miRNAs. MiR-8069 was deregulated in the longitudinal assessment only in DaT-negative L2NMC but not in the DaT-positive group, thus suggesting early deregulation prior to DaT-SPECT decline for this miRNA. Other miRNAs showed expression variations in only one of the two follow-up time points (miR-122-5p, miR-185-5p, miR-221-3p, miR-29c-3p, and miR-4505) and require further investigation. Lastly, miR-3196, which was found differentially expressed in all G2019S carriers groups including L2PD in the cross-sectional analysis, did not show L2NMC longitudinal changes compared to baseline, thus indicating that the deregulation of miR-3196 was steady across all G2019S carrier stages and did not depend on DaT-SPECT status. Conversely, miR-122-5p was differentially expressed in the L2PD validation group but also in time point 3 from both DaT-positive and DaT-negative L2NMC of the longitudinal analysis, potentially suggesting dynamic levels of this miRNA which need further investigation. Altogether, we observed that, compared to DaT-negative and DaT-positive L2NMC baselines, the expression levels of miRNAs deregulated at PD premotor stages are dynamic and can vary across time, at least during the 8-year follow-up period of this study.
Biological enrichment analysis
Lastly, we performed a biological enrichment analysis exploring the functionality of only experimentally validated genes from the miRTarbase, which are described to be targeted by the candidate miRNAs associated with the G2019S mutation. To that end, we used the top 10 miRNAs from each comparison from the discovery study. We found a higher number of target genes in iPD patients than in G2019S carriers, and iPD was also the only group surpassing the FDR-multiple testing adjustment (Table 4). Enriched biological functions in iPD differed from G2019S carriers and included gene expression, AKT, TGFb signaling, and senescence/TP53. In G2019S carriers, top deregulated pathways included Rho GTPases in DaT-negative and DaT-positive L2NMC and NOTCH signaling in DaT-positive L2NMC and L2PD. These pathways identified in G2019S carriers are involved in dendritic development and axonal arborization and have been extensively associated with LRRK2 biological functions before32,33,34.
The lack of informative biomarkers hampers the prediction of disease progression in G2019S L2NMC35. Here, we profiled serum miRNAs in a cohort of G2019S carriers from Spain stratified by DaT-SPECT. We observed dynamic miRNA expression profiles across the continuum of progression stages and identified 8 validated DEmiR in DaT-negative L2NMC, 6 in DaT-positive L2NMC, and one in L2PD. The strongest miRNA deregulation was in asymptomatic G2019S carriers, occurred along with the progressive DaT-SPECT decline before motor manifestation, and seemed to attenuate after the diagnosis of L2PD. Moreover, by an 8-year follow-up of DaT-negative and DaT-positive L2NMC, we detected sustained longitudinal variation of 11 DEmiR compared to their baselines. Our study identified specific miRNA changes in PD prodromal stages before motor manifestation, especially in DaT-positive L2NMC who are at a higher risk of PD compared to the general population. Moreover, we identified 4 miRNAs with a reasonable discriminative power to discern pheno-converted vs. non-pheno-converted G2019S carriers, which hold promise as early progression biomarkers for L2PD.
In iPD, we found stronger miRNA deregulation than in G2019S carriers and a higher number of miRNA-targeted genes. These findings are relevant given that L2PD is used to model iPD based on their similar clinical features36, yet with a certain degree of motor and non-motor heterogeneity37 and a slower progression described for L2PD38,39. Thus, at the molecular level, we also found different miRNA profiles between L2PD and iPD with a total of 46 DEmiR. As a possible interpretation, LRRK2 has been shown to directly interact with the Argonaute-2 component of the RNA-induced silencing complex (RISC)40,41. Therefore, unlike iPD, miRNA deregulation in LRRK2 carriers could be partially mediated by changes in the miRNA machinery related to the pathogenic activity of mutant LRRK2. Similarly, two earlier studies showed distinct miRNA fingerprints in iPD and monogenic PD patients with LRRK2, SNCA, or GBA mutations31,42. In addition, miR-19b-3p and miR-29c-3p were previously associated with iPD25,26,29,30,43,44 or idiopathic RBD27,28, and were also deregulated in our study only in iPD but not in G2019S carriers. Altogether, these results align with previous findings31,42 indicating group-specific miRNA deregulation between iPD and L2PD and an overall greater miRNA deregulation effect in iPD than in L2PD, which is compliant with the complex multifactorial etiology of iPD45,46.
Ours is the first study addressing miRNA changes in PD premotor stages, i.e., G2019S carriers with and without DaT-SPECT alterations, during an extended follow-up of 8 years. In G2019S carriers, we found that miRNA changes were more prominent in L2NMC than L2PD, suggesting an attenuation of miRNA deregulation after the diagnosis of PD. Specifically, we found 7 DEmiR deregulated in L2NMC both cross-sectional and longitudinally (miR-122-5p, miR-16-5p, miR-185-5p, miR-451a, miR-4505, miR-221-3p, and miR-8069). Apart from miR-8069, which is novel, six of these miRNAs were earlier described in PD patients with overt disease. Thus, a transcriptome study identified miR-4505 in L2PD blood47. Another RNA-seq study using PPMI cohorts found altered miR-122-5p, miR-16-5p, miR-185-5p, and miR-451a in monogenic PD with LRRK2, SNCA, or GBA mutations, and also, miR-16-5p and miR-451a in iPD31. Lastly, miR-185-5p and miR-221-3p are part of a 5-miRNA panel discriminating iPD serum from controls48. Collectively, these studies support the potential of miRNAs from our study as candidate biomarkers of early PD progression before motor manifestation.
In light of our findings, one hypothesis is that the G2019S pathogenic mutation, which leads to a toxic gain of kinase function of LRRK249, is also associated with miRNA deregulation processes in early premotor stages, which attenuate after motor manifestation in L2PD. Other studies described early molecular deregulation in subjects at-risk of PD before the clinical diagnosis. Thus, several reports showed a higher transcriptomic deregulation in L2NMC than in L2PD47 (L2NMC/L2PD ratio of 1.64) or in PD prodromal stages than in manifested PD (L2NMC/L2PD ratio of 2.36)50. In our longitudinal miRNA assessment of DaT-negative and DaT-positive L2NMC, we also found progressive miRNA variation after 4 and 8 years compared to their respective baselines. These results align with a 3-year longitudinal RNA-seq study in a PPMI cohort including iPD and monogenic L2PD reporting dynamic miRNA levels across the progression of PD31. Similarly, our 8-year longitudinal follow-up in G2019S carriers indicates dynamic miRNA expression changes in premotor stages of PD.
Overall, exploring the prodromal stage of PD is essential to elucidate early disease mechanisms and identify early PD progression biomarkers51,52. Illustratively, a recent cerebrospinal fluid (CSF) study reported that levels of total and oligomeric α-synuclein and TNF-α discriminate L2NMC from L2PD and iPD, and controls53, thus proposing these candidates as risk biomarkers in prodromal PD stages. Moreover, another study has recently identified specific phospho-protein changes associated with the G2019S mutation in L2NMC54. Similarly, here we found specific miRNA deregulation in G2019S carriers with and without DaT-SPECT decline before the diagnosis of PD. Thus, as earlier suggested54,55, a relevant implication of our findings is that initiation of LRRK2 inhibitors treatment in L2NMC before motor manifestation represents an attractive option to investigate in clinical trials. In this context, miRNAs detected in L2NMC before motor manifestation warrant further investigation as candidate early progression biomarkers. Specifically, we identified a combination of 4 miRNAs (miR-4505, miR-8069, miR-6125, and miR-451a) that exhibits an AUC of 0.82 in discriminating 8-year followed-up non-pheno-converted DaT-positive L2NMC from pheno-converted L2PD patients. Hence, these 4 miRNAs hold potential as candidate pheno-conversion biomarkers and could be prioritized in subsequent longitudinal studies on LRRK2 G2019S carriers or other prodromic PD cohorts.
Lastly, we performed a restrictive functional enrichment analysis using experimentally validated target genes only from the top 10 deregulated miRNAs from each discovery group. We found that the biological enrichment in iPD was substantially different from G2019S carriers and targeted the AKT and TGF-beta pathways, which are mostly related to the immune system and inflammation56,57. In all G2019S carriers, we found consistent deregulation of Rho GTPases and NOTCH signaling. These pathways play a key role in axonal guidance by regulating neural arborization and dendritic development and are involved in neurodegenerative processes58,59. Moreover, the Rho GTPase RAC1 and NOTCH are functionally related to LRRK2, and can be affected by LRRK2 mutations32,33. By mass-spectrometry phospho-proteome analysis, Rho GTPases were also reported among the top deregulated pathways in peripheral blood cells from G2019S carriers54. Lastly, Rho GTPases and NOTCH have also been proposed as therapeutic targets for PD58,60. Altogether, these studies further strengthen a plausible role for miRNA deregulation in G2019S carriers.
Despite some exciting observations on differential miRNA expression profiles in L2NMC, our study has limitations. First, we performed an extensive longitudinal study of L2NMC characterized by DaT-SPECT, but did not longitudinally followed-up L2PD, iPD, or controls. Second, during our 8-year follow-up period, only 4 out of 20 DaT-positive L2NMC (20%) pheno-converted; therefore, more extended follow-up periods are needed in future studies. Third, given that not all L2NMC are expected to develop PD, our study did not explore other risk or protective factors modulating the penetrance of mutations in LRRK2 beyond miRNAs. Fourth, no other PD-associated mutations other than in LRRK2 gene were screened. Lastly, a limitation of many miRNA studies is the inter-lab variability regarding biospecimens, techniques, and normalizers and the lack of consensus guidelines, thus eventually limiting cross-lab reproducibility.
In summary, our study identifies novel miRNA alterations co-occurring with progressive DaT-SPECT decline in premotor stages of PD before the diagnosis of PD. If validated, some of the identified miRNAs hold potential as early progression biomarkers or pheno-conversion in premotor G2019S carriers. These findings may have implications for early PD detection or early neuroprotective strategies when available.
All subjects provided written informed consent, and the Ethics Committees of IDIBAPS-Hospital Clínic de Barcelona and Hospital Marqués de Valdecilla approved the study. Serum samples and clinical data from probands were collected at the Movement Disorder units from Hospital Clínic de Barcelona and Hospital Marqués de Valdecilla in Santander (Table 1). By center and group, our cohort included n = 20 DaT-negative G2019S L2NMC (7 from Barcelona/13 from Santander), n = 20 DaT-positive G2019S L2NMC (7/13), n = 20 G2019S L2PD patients (7/13), n = 19 iPD cases (7/12), and n = 40 healthy controls (27/13). We additionally recruited n = 19 L2PD patients and n = 20 controls, all from Barcelona, to further assess miRNA findings in a second L2PD cohort (total studied n = 158). PD patients were clinically diagnosed according to the UK PD Society Brain Bank criteria, except for the fact that more than one affected relative with PD was not an exclusion criterion61. We genotyped all LRRK2 G2019S carriers and iPD patients for the LRRK2 G2019S and R1441G/C/H mutations using commercial Taqman SNP assays-on-demand on a StepOnePlus™ Real-time PCR System. No systematic sequencing was performed to exclude additional mutations causing monogenic PD. We characterized G2019S L2NMC by DaT-SPECT imaging using 123I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)-nortropane (123I-FP-CIT) SPECT. Images were acquired in a dual‐headed gamma camera (E‐Cam, Siemens). L2NMC were accordingly dichotomized into DaT-negative (normal) and DaT-positive (abnormal dopaminergic function) SPECT status. For longitudinal assessment of L2NMC, subjects were clinically followed-up on average every 2 years and, beyond the baseline, donated two additional serum samples, thus covering a follow-up period above 8 years. In this period, 4 DaT-positive L2NMC (20%) from Santander developed motor symptoms and met the criteria for clinical PD diagnosis.
Serum miRNA isolation
A total of 5 ml peripheral blood was collected in tubes without anticoagulant (BD Vacutainer) and centrifuged 10 min at 1500 × g and 4 °C. Serum was aliquoted into polypropylene CryoTubes (Greiner Bio-One) and kept at −80 °C until use. Total miRNA enriched RNA was extracted using the miRNeasy Serum/Plasma Kit (QIAGEN #217184). As a carrier for miRNA isolation, we added 2 ul of diluted yeast tRNA (Invitrogen #AM7119) into 200 ul of serum for a final concentration of 10 ug/ml. RNA concentration was determined for all samples on a NanoDrop ND-3300 fluorospectrometer (Thermo Fisher Sci.), and miRNA quality was evaluated for a subset of randomly selected samples by electropherogram using an Bioanalizer Small RNA Kit (Agilent #5067-1548).
Genome-wide miRNA analysis
In the discovery genome-wide miRNA expression analysis, serum miRNA samples were hybridized individually and blind to operator for 42 h onto Affymetrix GeneChip miRNA 4.0 Array (Applied Biosystems #902411; product datasheet), which contains probes for more than 4603 human miRNAs (2578 mature miRNAs and 2025 pre-miRNAs). Images were scanned using an Affymetrix GeneChip Scanner 3000 7G. Files generated by the Affymetrix GeneChip Command Console (AGCC) were processed with the Expression Console software to determine the data quality. Microarray raw data were analyzed using Partek Genomic Suite v7.0 software applying the robust multi-array average (RMA) background correction model, which allows the relative comparison of miRNA abundance in different arrays. Only miRNAs with fluorescence detection values above 2.4 arbitrary units and a significant expression p value below 0.05 compared to background were considered expressed in human serum samples. In line with previous reports, up to 10% of the mature human miRNA screened in the array were expressed in human serum62. For differential miRNA expression analysis, we used the global normalization method adjusting by sex, age, and hybridization date. We compared the miRNA expression levels of DaT-negative L2NMC, DaT-positive L2NMC, L2PD, or iPD with controls, or among study groups (DaT-negative vs. DaT-positive L2NMC, DaT-positive L2NMC vs. L2PD, and L2PD vs. iPD) in a two-tailed Student’s t test. We defined as candidate differentially expressed miRNAs for subsequent RT-qPCR assessment those miRNAs with a significance double criterion of a fold-change above |1.5| and a p value below 0.05.
RT-qPCR miRNA analysis
Serum miRNA samples were reverse-transcribed and pre-amplified using TaqMan Advanced miRNA cDNA Synthesis Kit (Thermo Fisher Sci. #A28007) in a VeritiTM 96-well Thermal Cycle (Applied Biosystems #4375786). For each miRNA, cDNA pre-amplified products were quantified using TaqMan Fast Advanced Master Mix (Thermo Fisher Sci. #4444557) and TaqMan Advanced miRNA Assays (Thermo Fisher Sci. #A25576). Reactions were performed per duplicate on a TaqMan® StepOnePlus™ Real-Time PCR System (Applied Biosystems) using 96-well real-time PCR plates at a final volume of 10 µl. After discarding commercially available assays which did not amplify at a minimum quality level in serum samples, by real-time quantitative PCR (RT-qPCR) we tested a total of 12 candidate miRNAs. These included 10 candidate DEmiR detected by the array (miR-122-5p, miR-16-5p, miR-185-5p, miR-19b-3p, miR-22-3p, miR-221-3p, miR-29c-3p, miR-3196, miR-4505, miR-451a, miR-6125 and miR-8069), and 2 additional candidate miRNA earlier reported in iPD (miR-29c-3p)25,27 or well-established PD prodromal stages (idiopathic RBD) (miR-451a)28. Among the candidate miRNAs selected from the array, miR-185-5p, miR-6125, miR-3196, miR-4505, and miR-22-3p were detected in more than one comparison (Supplementary Table 1), and miR-19b-3p and miR-221-3p were previously reported as deregulated miRNAs in PD25 and idiopathic RBD28. For normalization, we selected miR-320a-3p and miR-6727-5p as endogenous references. These miRNAs were unbiasedly nominated among the miRNAs showing the most stable expression across all samples using the NormFinder software63. For relative quantification, we applied the ∆∆CT method using the DataAssist v3.0 software (Applied Biosystems). The maximum allowable CT value was set at 35. Statistical significance levels for RT-qPCR validated differentially expressed miRNAs (DEmiR) were established at a fold-change difference above |1.5|, and a Benjamini-Hochberg FDR adjusted p value below 0.05 under a two-tailed Student’s t test.
To infer the probability of each patient to undergo pheno-conversion based on miRNA expression values, logistic regression models were fitted by using the caret framework in R, and including leave-one-out cross-validation to reduce overfitting of predicted data. The discriminative ability of the differentially expressed miRNAs was assessed by means of the area under the curve (AUC) on a receiver operating characteristic (ROC) curve employing the pROC package.
Biological enrichment analysis
As a functional analysis, we selected only the 10 top miRNAs identified in each genome-wide discovery group as compared to controls and performed a miRNA target gene analysis using the Mienturnet tool (link). Using the miRTarbase database, we further filtered-in only experimentally validated target genes which were targeted by one or more miRNAs. Lastly, we performed a biological enrichment analysis using the pathway database Reactome in Webgestalt online source (link) under the significance cut-off of a Benjamini-Hochberg FDR adjusted p value below 0.05.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
The GeneChip miRNA array data are available at the genome expression omnibus (GEO) under the accession code GSE221543.
Elbaz, A., Carcaillon, L., Kaba, S. & Ms, F. Epidemiology of Parkinson’s disease. Rev. Neurol. 172, 14–26 (2016).
Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839–840 (1997).
Dickson, D. W. et al. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol. 8, 1150–1157 (2009).
Sveinbjornsdottir, S. The clinical symptoms of Parkinson’s disease. J. Neurochem. 139, 318–324 (2016).
Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30, 1591–1601 (2015).
Lesage, S. & Brice, A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18, 48–59 (2009).
Paisán-Ruíz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44, 595–600 (2004).
Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron 44, 601–607 (2004).
Ruiz-Martínez, J. et al. Penetrance in Parkinson’s disease related to the LRRK2 R1441G mutation in the Basque country (Spain). Mov. Disord. 25, 2340–2345 (2010).
Sierra, M. et al. High frequency and reduced penetrance of lRRK2 g2019S mutation among Parkinson’s disease patients in Cantabria (Spain). Mov. Disord. 26, 2343–2346 (2011).
Hentati, F. et al. LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance. Neurology 83, 568–569 (2014).
Marder, K. et al. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology 85, 89–95 (2015).
Lee, A. J. et al. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry. Mov. Disord. 32, 1432–1438 (2017).
Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004).
Oliveira, S. R. et al. Circulating inflammatory mirnas associated with parkinson’s disease pathophysiology. Biomolecules 10, 1–13 (2020).
Hu, Y. B. et al. miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson’s disease. Cell Death Dis. 10, 589 (2019).
Chen, X. et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18, 997–1006 (2008).
Danborg, P. B., Simonsen, A. H., Waldemar, G. & Heegaard, N. H. H. The potential of microRNAs as biofluid markers of neurodegenerative diseases-a systematic review. Biomarkers 19, 259–268 (2014).
Gaig, C. et al. Mutations in Spanish patients with Parkinson disease. Arch. Neurol. 63, 6–11 (2006).
Sánchez-Rodríguez, A. et al. Serial DaT-SPECT imaging in asymptomatic carriers of LRRK2 G2019S mutation: 8 years’ follow-up. Eur. J. Neurol. 28, 4204–4208 (2021).
Kägi, G., Bhatia, K. P. & Tolosa, E. The role of DAT-SPECT in movement disorders. J. Neurol. Neurosurg. Psychiatry 81, 5–12 (2010).
Scherfler, C. et al. Role of DAT-SPECT in the diagnostic work Up of Parkinsonism. Mov. Disord. 22, 1229–1238 (2007).
Sierra, M. et al. Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease. Neurology 89, 439 LP–439444 (2017).
Iranzo, A. et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 10, 797–805 (2011).
Botta-Orfila, T. et al. Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson’s disease. J. Neurosci. Res. 92, 1071–1077 (2014).
Cao, X. Y. et al. MicroRNA biomarkers of Parkinson’s disease in serum exosome-like microvesicles. Neurosci. Lett. 644, 94–99 (2017).
Fernández-Santiago, R. et al. MicroRNA association with synucleinopathy conversion in rapid eye movement behavior disorder. Ann. Neurol. 77, 895–901 (2015).
Soto, M. et al. Serum microRNAs predict isolated rapid eye movement sleep behavior disorder and Lewy body diseases. Mov. Disord. 37, 2086–2098 (2022).
Bai, X. et al. Downregulation of blood serum microRNA 29 family in patients with Parkinson’s disease. Sci. Rep. 7, 1–7 (2017).
Ma, W. et al. Serum miR-221 serves as a biomarker for Parkinson’s disease. Cell Biochem. Funct. 34, 511–515 (2016).
Kern, F. et al. Deep sequencing of sncRNAs reveals hallmarks and regulatory modules of the transcriptome during Parkinson’s disease progression. Nat. Aging 1, 309–322 (2021).
Chan, D., Citro, A., Cordy, J. M., Shen, G. C. & Wolozin, B. Rac1 protein rescues neurite retraction caused by G2019s leucine-rich repeat kinase 2 (LRRK2). J. Biol. Chem. 286, 16140–16149 (2011).
Imai, Y. et al. The Parkinson’s disease-associated protein kinase LRRK2 modulates Notch signaling through the endosomal pathway. PLoS Genet. 11, 1–30 (2015).
Redmond, L. & Ghosh, A. The role of Notch and Rho GTPase signaling in the control of dendritic development. Curr. Opin. Neurobiol. 11, 111–117 (2001).
Tolosa, E., Garrido, A., Scholz, S. W. & Poewe, W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 20, 385–397 (2021).
Aasly, J. O. et al. Clinical features of LRRK2-associated Parkinson’s disease in Central Norway. Ann. Neurol. 57, 762–765 (2005).
Marras, C. et al. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson’s disease. Mov. Disord. 31, 1192–1202 (2016).
Saunders-Pullman, R. et al. Progression in the LRRK2-associated Parkinson disease population. JAMA Neurol. 75, 312–319 (2018).
Kestenbaum, M. & Alcalay, R. N. Clinical features of LRRK2 carriers with Parkinson’s disease. Adv. Neurobiol. 14, 31–48 (2017).
Gonzalez-Cano, L., Menzl, I., Tisserand, J., Nicklas, S. & Schwamborn, J. C. Parkinson’s disease-associated mutant LRRK2-mediated inhibition of miRNA activity is antagonized by TRIM32. Mol. Neurobiol. 55, 3490–3498 (2018).
Gehrke, S., Imai, Y., Sokol, N. & Lu, B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466, 637–641 (2010).
Ravanidis, S. et al. Circulating brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson’s disease. Mov. Disord. 35, 457–467 (2020).
Martins, M. et al. Convergence of mirna expression profiling, α-synuclein interacton and GWAS in Parkinson’s disease. PLoS ONE 6, e25443 (2011).
Gui, Y. X., Liu, H., Zhang, L. S., Lv, W. & Hu, X. Y. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget 6, 37043–37053 (2015).
Ascherio, A. & Schwarzschild, M. A. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 15, 1257–1272 (2016).
Fernández-Santiago, R. & Sharma, M. What have we learned from genome-wide association studies (GWAS) in Parkinson’s disease? Ageing Res. Rev. 79, 101648 (2022).
Infante, J. et al. Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson’s disease. Neurobiol. Aging 38, 214.e1–214.e5 (2015).
Ding, H. et al. Identification of a panel of five serum miRNAs as a biomarker for Parkinson’s disease. Park. Relat. Disord. 22, 68–73 (2016).
Marchand, A., Drouyer, M., Sarchione, A., Chartier-Harlin, M. C. & Taymans, J. M. LRRK2 phosphorylation, more than an epiphenomenon. Front. Neurosci. 14, 1–21 (2020).
Craig, D. W. et al. RNA sequencing of whole blood reveals early alterations in immune cells and gene expression in Parkinson’s disease. Nat. Aging 1, 734–747 (2021).
Schapira, A. H. V. & Tolosa, E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat. Rev. Neurol. 6, 309–317 (2010).
Marek, K. & Jennings, D. Can we image premotor Parkinson disease? Neurology 72, S21 LP–S21 26 (2009).
Majbour, N. K. et al. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers. Transl. Neurodegener. 9, 1–10 (2020).
Garrido, A. et al. Differential phospho-signatures in blood cells identify LRRK2 G2019S carriers in Parkinson’s disease. Mov. Disord. 37, 1004–1015 (2022).
Tolosa, E., Vila, M., Klein, C. & Rascol, O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat. Rev. Neurol. 16, 97–107 (2020).
Sangphech, N., Osborne, B. A. & Palaga, T. Notch signaling regulates the phosphorylation of Akt and survival of lipopolysaccharide-activated macrophages via regulator of G protein signaling 19 (RGS19). Immunobiology 219, 653–660 (2014).
Villegas, S. N. et al. PI3K/Akt cooperates with oncogenic Notch by inducing nitric oxide-dependent inflammation. Cell Rep. 22, 2541–2549 (2018).
DeGeer, J. & Lamarche-Vane, N. Rho GTPases in neurodegeneration diseases. Exp. Cell Res. 319, 2384–2394 (2013).
Ables, J. L., Breunig, J. J., Eisch, A. J. & Rakic, P. Not(ch) just development: Notch signalling in the adult brain. Nat. Rev. Neurosci. 12, 269–283 (2011).
Musilli, M. et al. Therapeutic effects of the Rho GTPase modulator CNF1 in a model of Parkinson’s disease. Neuropharmacology 109, 357–365 (2016).
Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson’ s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181–184 (1992).
Umu, S. U. et al. A comprehensive profile of circulating RNAs in human serum. RNA Biol. 15, 242–250 (2018).
Andersen, C. L., Jensen, J. L. & Ørntoft, T. F. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 64, 5245–5250 (2004).
We thank the patients and their relatives for their generous and continued collaboration in this project. M.F. was funded by María de Maeztu programme (grant #MDM-2017-0729) to the Parkinson’s disease and Movement Disorders group of the Institut de Neurociències (Universitat de Barcelona). S.L. was beneficiary of a PFIS fellowship from Instituto de Salud Carlos III (ISCIII) and co-funded by the European Regional Development Fund (ERDF) (grant #FI18/00221). J.C. was supported by a Miguel Servet grant from Instituto de Salud Carlos III (ISCIII) co-funded by the European Union (grant #CPII18/00026). R.F.-S. was supported by the Miguel Servet (grant #CP19/00048), FIS (grant #FIS20-PI20/00659) and PFIS (grant #FI21/00104) programs from the Instituto de Salud Carlos III (ISCIII) co-funded by the European Union, and also by a Jóvenes Investigadores (JIN) grant of the Spanish Ministry of Economy and Competitiveness (MINECO) and the Agencia Estatal de Investigación (AEI) (AEI/FEDER/UE) (grant #SAF2015-73508-JIN). We also thank the support from the AGAUR program from the Generalitat de Catalunya (grant AGAUR#2017SGR1502) and the Spanish Network for Research on Neurodegenerative Disorders (CIBERNED)—ISCIII (CIBERNED: CB06/05/0018-ISCIII).
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Soto, M., Fernández, M., Bravo, P. et al. Differential serum microRNAs in premotor LRRK2 G2019S carriers from Parkinson’s disease. npj Parkinsons Dis. 9, 15 (2023). https://doi.org/10.1038/s41531-023-00451-x